Treats hypertension. ANDA 215560, held by Novitium Pharma. Atenolol; Chlorthalidone.
As of Nov 22, 2026, ANDA 215560 (Atenolol and Chlorthalidone), held by Novitium Pharma, was first approved by FDA on Oct 25, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS & USAGE Atenolol and Chlorthalidone Tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 25, 2021 | Original application | Approved | None posted |
| Atenolol and Chlorthalidone50MG;25MG · tablet;oral | Atenolol; Chlorthalidone | Rx |
| Atenolol and Chlorthalidone100MG;25MG · tablet;oral | Atenolol; Chlorthalidone | Rx |
| Sep 23, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 25, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters